Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kissei Pharmaceutical Co ( (JP:4547) ) just unveiled an announcement.
Kissei Pharmaceutical Co., Ltd. has announced the launch of TAVALISSE, a spleen tyrosine kinase inhibitor for treating chronic idiopathic thrombocytopenic purpura (ITP), in South Korea through its partner JW Pharmaceutical Corporation. This launch marks a significant expansion of TAVALISSE, which has already been introduced in the United States, Europe, Canada, and the Middle East, and is expected to strengthen Kissei’s position in the treatment of ITP, an intractable disease, while potentially impacting its financial results for the fiscal year ending March 2026.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co., Ltd. is a company operating in the pharmaceutical industry, focusing on the development and commercialization of treatments for various medical conditions. The company is known for its work on spleen tyrosine kinase inhibitors, with a market focus that includes regions such as Japan, China, South Korea, and Taiwan.
Average Trading Volume: 97,572
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen164.6B
Learn more about 4547 stock on TipRanks’ Stock Analysis page.